CSL Limited (ASX:CSL) enters the new trading week following a challenging five-session losing streak that erased 7.4% of its market value. Shares closed Friday at A$114.22, down 1.3% on the day, significantly underperforming the broader S&P/ASX 200 index, which slipped just 0.28% over the same period. The ASX cash market was closed at the time of publication, with pre-open trading scheduled to begin at 07:00 AEST.
The primary catalyst for the week's sell-off was Friday's update on HEMGENIX, CSL's gene therapy for hemophilia B. The company reported that it had supplied the treatment to 22 patients in both commercial and clinical trial settings since limited supply resumed in April. While the update was framed as positive, the numbers underscore the scale challenge facing the therapy.
HEMGENIX carries a U.S. list price of US$3.5 million per patient. Applying that price to the 22 patients yields a gross list-value proxy of US$77 million. However, this figure represents only about 0.5% of CSL's FY26 revenue guidance of US$15.2 billion, highlighting the therapy's minimal near-term financial impact. The estimate is preliminary and not reported revenue, as the count includes clinical-trial use, and list prices do not necessarily reflect actual transaction prices.
CSL underperformed the index by approximately 7.1 percentage points over the five sessions. Dr. Deborah Long, CSL's senior vice president for medical affairs, described the progress as "encouraging," noting that more than 100 patients have received commercial HEMGENIX treatment globally since approval. Nevertheless, the company continues to characterize supply as limited and stated it is "actively managing" availability.
A Saturday report citing a UBS Group note maintained a target price of A$158 for CSL, representing a potential 38% upside from Friday's close. However, UBS also forecast flat profit for FY27, attributing the outlook to a rapid decline in contributions from Vifor, the iron-deficiency treatment specialist CSL acquired in 2022.
The broader earnings reset remains a key theme. CSL's May strategic review set FY26 revenue near US$15.2 billion and underlying net profit after tax and amortization (NPATA) near US$3.1 billion, both at constant currency. The review identified approximately US$650 million in revenue headwinds, including US$300 million from U.S. immunoglobulin inventory adjustments, US$200 million from China albumin pressures, and US$150 million from other factors including HEMGENIX. CSL also flagged about US$5 billion in additional non-cash, pre-tax impairments across FY26 and FY27.
CEO Gordon Naylor acknowledged that financial benefits from recent initiatives "will take longer" to materialize. The week ahead includes Australia's June CPI release on Wednesday at 11:30 AEST and the Federal Reserve's July 28–29 meeting. CSL's next scheduled company update is its full-year result on August 18, with a webcast starting at 10:00 AEST.
The stock's Monday open will test whether HEMGENIX can interrupt the five-session slide. Key risks include limited HEMGENIX supply, realized prices that may trail list prices, ongoing China albumin and U.S. inventory shifts, and pending impairment reviews that continue to cloud the earnings outlook.
